Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression
/in Hypernephroma, International Publications /von 2007-04-20 / Clin. Immunol. 2007 Jun;123(3):298-310DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
/in Dendritic Cells, Hypernephroma, International Publications /von 2007-04-19 / Cancer Immunol. Immunother. 2007 Nov;56(11):1817-29Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine
/in Colorectal Cancer, International Publications /von 2007-04-18 / Cancer Immunol. Immunother. 2007 Oct;56(10):1597-604Immunology and immunotherapy approaches for prostate cancer
/in International Publications, Prostate Cancer /von 2007-04-10 / Prostate Cancer Prostatic Dis. 2007;10(3):224-36Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia
/in Chronic Leukemia, International Publications /von 2007-04-04 / Br. J. Haematol. 2007 May;137(4):297-306In vitro induction of apoptosis in tumor cells by inactivated NDV and IAV
/in International Publications, Newcastle Disease Virus /von 2007-04-01 / Cancer Biother. Radiopharm. 2007 Apr;22(2):200-5Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells–a pilot study
/in International Publications, Prostate Cancer /von 2007-04-01 / Prostate 2007 Apr;67(5):500-8Dendritic cell-based active specific immunotherapy for malignant glioma
/in Glioblastoma, International Publications /von 2007-04-01 / Expert Opin Biol Ther 2007 Apr;7(4):439-48Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model
/in Glioblastoma, International Publications /von 2007-04-01 / J. Neurosurg. 2007 Apr;106(4):638-45IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de